Literature DB >> 211144

Incidence and significance of hepatitis B e antigen and antibody in postnecrotic cirrhosis and primary hepatocellular carcinoma.

P Coursaget, P Maupas, A Goudeau, J Drucker.   

Abstract

A study of the serological markers of Hepatitis B virus (HBV) including e antigen (HBe Ag) and antibody against HBe Ag (anti-HBe) was performed in Senegalese patients suffering from cirrhosis and primary hepatocellular carcinoma, and in a control group (blood donors). It was not possible to diagnose additional HBV infections in primary hepatocellular carcinoma patients using HBe Ag or anti-HBe Ab alone as serological markers. The lower prevalence of HBe Ag among primary hepatocellular carcinoma patients as compared with cirrhotic patients suggests that active replication of HBV becomes increasingly defective during the course of the malignant process.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 211144      PMCID: PMC274975          DOI: 10.1128/jcm.7.4.394-395.1978

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  16 in total

1.  Incidence and meaning of the "e" determinant among hepatitis-B-antigen positive patients with acute and chronic liver diseases. Report from the Copenhagen Hepatitis Acuta Programme.

Authors:  J O Nielsen; O Dietrichson; E Juhl
Journal:  Lancet       Date:  1974-10-19       Impact factor: 79.321

2.  Antibody to hepatitis-B-virus core in man.

Authors:  J H Hoofnagle; R J Gerety; L F Barker
Journal:  Lancet       Date:  1973-10-20       Impact factor: 79.321

3.  New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants.

Authors:  L O Magnius; J A Espmark
Journal:  J Immunol       Date:  1972-11       Impact factor: 5.422

4.  Hepatitis-associated antigen in Ugandan patients with hepatocellular carcinoma.

Authors:  C L Vogel; P P Anthony; N Mody; L F Barker
Journal:  Lancet       Date:  1970-09-26       Impact factor: 79.321

5.  A new antigen-antibody system. Clinical significance in long-term carriers of hepatitis B surface antigen.

Authors:  L O Magnius; A Lindholm; P Lundin; S Iwarson
Journal:  JAMA       Date:  1975-01-27       Impact factor: 56.272

6.  Anti-e in primary hepatic carcinoma.

Authors:  B G Werner; B L Murphy; J E Maynard; B Larouzé
Journal:  Lancet       Date:  1976-03-27       Impact factor: 79.321

7.  e antigen and anti-e in HBsAg carriers.

Authors:  S V Feinman; B Berris; J C Sinclair; D M Wrobel; B L Murphy; J E Maynard
Journal:  Lancet       Date:  1975-12-13       Impact factor: 79.321

8.  Dane particles, DNA polymerase, and e-antigen in two different categories of hepatitis B antigen carriers.

Authors:  E Nordenfelt; L Kjellén
Journal:  Intervirology       Date:  1975       Impact factor: 1.763

9.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  E Tabor; R J Gerety; C L Vogel; A C Bayley; P P Anthony; C H Chan; L F Barker
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

10.  [Hepatitis B virus and primary liver carcinoma: evidences for a filiation hepatitis B, cirrhosis and primary liver cancer].

Authors:  P Maupas; P Coursaget; A Goudeau; J Drucker; M Sankale; J Linhard; G Diebolt
Journal:  Ann Microbiol (Paris)       Date:  1977 Feb-Mar
View more
  2 in total

1.  Incidence and significance of hepatitis B and A virus serologic markers in Greek cirrhotic patients.

Authors:  G Theodoropoulos; G Hadzis
Journal:  Gastroenterol Jpn       Date:  1985-10

2.  Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.

Authors:  Donatien Serge Mbaga; Sebastien Kenmoe; Cyprien Kengne-Ndé; Jean Thierry Ebogo-Belobo; Gadji Mahamat; Joseph Rodrigue Foe-Essomba; Marie Amougou-Atsama; Serges Tchatchouang; Inès Nyebe; Alfloditte Flore Feudjio; Ginette Irma Kame-Ngasse; Jeannette Nina Magoudjou-Pekam; Lorraine K M Fokou; Dowbiss Meta-Djomsi; Martin Maïdadi-Foudi; Sabine Aimee Touangnou-Chamda; Audrey Gaelle Daha-Tchoffo; Abdel Aziz Selly-Ngaloumo; Rachel Audrey Nayang-Mundo; Jacqueline Félicité Yéngué; Jean Bosco Taya-Fokou; Raoul Kenfack-Momo; Efietngab Atembeh Noura; Cynthia Paola Demeni Emoh; Hervé Raoul Tazokong; Arnol Bowo-Ngandji; Carole Stéphanie Sake; Etienne Atenguena Okobalemba; Jacky Njiki Bikoi; Richard Njouom; Sara Honorine Riwom Essama
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.752

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.